Avience Biomedicals Ltd.
SMEBSE₹196–208
₹ 22 Cr
1200 Shares
₹ 2,35,200
₹10
Financial Summary
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| 4,523.6 | 2,396.4 | |
| 73.15 | 40.86 | |
| 4,596.75 | 2,437.26 | |
| 3,378.8 | 1,986.01 | |
| 980.07 | 294.52 | |
| 723.18 | 214.11 |
Subscription Details
IPO Timeline
IPO Offer Start
18 Jun 2026
IPO Offer Ends
22 Jun 2026
25 Jun 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Part finances the capital expenditure towards setting up of a new | 140.453 |
| 2 | Funding the working capital requirement of our Company | 82.5 |
| 3 | General Corporate Purposes | 39.721 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
92.85%
Promoter stake
Post-IPO
64.59%
Promoter stake
Offered to Public
10,44,000
shares
Post Share Capital
35,42,885
shares
About the Company
Avience Biomedicals Limited is a medical consumable company dedicated to manufacturing of Vitro-Diagnostic (IVD) productsand medical devices in Noida, Uttar Pradesh, India. In vitro diagnostics (IVDs) are tests that can detect disease, conditions andinfections. In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, asopposed to in vivo tests, which are conducted in the body itself. In vitro tests can be done in laboratories, health care facilities oreven in the home. The tests themselves can be performed on a variety of instruments ranging from small, handheld tests to complexlaboratory instruments.Avience Biomedicals Limited commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM),Covid, Human Immunodeficiency Viruses (HIV), HBs AG, Malaria, Dengue and others aimed at aiding medical institutions withaffordable and good-quality solutions. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits toinclude a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents,showcasing a dedication to addressing various healthcare needs. Being purely into B2B and B2G market, our products cater toPathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing,the Company also act as distributors and traders of medical equipments
Use of Proceeds
1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh2. Funding the Working Capital Requirement of our Company3. To meet out the General Corporate Purposes